This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Retain Henry Schein (HSIC) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Henry Schein (HSIC) on robust sales of PPE and COVID-19-related products.
Henry Schein (HSIC) Up 4.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 Stocks to Capitalize on Promising Dental Supplies Industry
by Trina Mukherjee
Despite the challenges thrown by the COVID-19 pandemic, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.
The Zacks Analyst Blog Highlights: Align Technology, Henry Schein, McKesson Corp and Becton, Dickinson and Co
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Align Technology, Henry Schein, McKesson Corp and Becton, Dickinson and Co
4 Dental Stocks to Watch on Likely Industry Turnaround
by Zacks Equity Research
The dental equipment market seems ready to grow as it continues to recover from the COVID-19 pandemic slump, making it prudent to look at names like Henry Schein (HSIC) and McKesson (MCK)
Henry Schein (HSIC) Q4 Earnings Top Estimates, Margins Dip
by Zacks Equity Research
Henry Schein (HSIC) sees robust segmental performance in Q4 boosted by strong rebound in sales, and solid demand for PPE and COVID-19-related products.
Henry Schein (HSIC) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of 4.17% and 10.70%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Henry Schein (HSIC)
by Zacks Equity Research
Henry Schein (HSIC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Henry Schein (HSIC) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Henry Schein (HSIC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Henry Schein (HSIC) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Henry Schein's (HSIC) medical business' PPE sales are likely to have maintained its momentum along with global recovery trends of the dental business during Q4.
The Zacks Analyst Blog Highlights: ResMed, Invacare, Fresenius, Henry Schein and Quest Diagnostics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ResMed, Invacare, Fresenius, Henry Schein and Quest Diagnostics
4 MedTech Underperformers Poised for a Turnaround in 2021
by Debanjana Dey
Here are some dirt-cheap MedTech value stocks which are expected to provide long-term gains in 2021.
Henry Schein (HSIC) Grows Inorganically, Closes JV, Buys Stake
by Zacks Equity Research
The developments are expected to strengthen Henry Schein's (HSIC) presence in high potential and still-untapped markets.
Can Value Investors Henry Schein (HSIC) Stock Right Now?
by Zacks Equity Research
Is Henry Schein (HSIC) a great pick from the value investor's perspective right now? Read on to know more.
Henry Schein (HSIC) Up 7.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Henry Schein (HSIC) Q3 Earnings Top Estimates, Margins Dip
by Zacks Equity Research
Henry Schein (HSIC) sees robust segmental performance in Q3 boosted by strong rebound in sales and solid demand for PPE and COVID-19-related products.
Henry Schein (HSIC) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of 43.06% and 16.55%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Earnings Due on Nov 2: STE, HSIC & More
by Urmimala Biswas
Several medical product stocks have come up with bullish earnings reports so far this reporting cycle. Let's see how STE, HSIC, PACB, INSP are poised ahead of their announcements.
Why Henry Schein (HSIC) Might Surprise This Earnings Season
by Zacks Equity Research
Henry Schein (HSIC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
3 Dental Supplies Stocks Set to Shine on the Industry's Upturn
by Trina Mukherjee
Despite the challenges thrown by the COVID-19 pandemic, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. CAH, WST and MCK are well positioned to gain from the prospects.
Henry Schein (HSIC) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Henry Schein's (HSIC) medical business' PPE sales are likely to have maintained its momentum along with global recovery trends of the dental business during Q3.
Henry Schein (HSIC) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Henry Schein (HSIC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Align (ALGN) Unveils New Product for Better Treatment Option
by Zacks Equity Research
Align Technology's (ALGN) latest product to aid in improving doctor performance and ensure better treatment planning.
Henry Schein Partners MouthWatch to Grow in Teledentistry
by Zacks Equity Research
Henry Schien's (HSIC) customer base is likely to benefit from the Teledent platform.
Henry Schein (HSIC) Enters Into New Dental Deal With Zyris
by Zacks Equity Research
Henry Schien (HSIC) is set to be the exclusive distributor of Zyris products like Isolite 3, Isovac 2, Isodry and the company's patented single-use Mouthpieces.